Newest Viral Hepatitis Data From AASLD 2022

In this episode, Stefan Zeuzem, MD, discusses new viral hepatitis data from AASLD 2022, including:

• Hepatitis B
• Prevention of HBV vertical transmission when HBIg is unavailable
• Therapeutic vaccination for HBV cure
• Antiviral therapy to prevent HCC in patients with CHB in the indeterminate phase
• Hepatitis delta
• HDV prevalence in ethnically diverse, urban, safety-net populations
• Bulevirtide ± pegIFN-α2a for chronic HDV in the French cATU study
• Bulevirtide monotherapy for patients with HDV and compensated cirrhosis in the HEP4Di study
• HDV functional cure with lonafarnib-based therapy
• Hepatitis C
• Integrated community HCV service for PWUD: the ITTREAT study
• Helios-3 study of treatment of people with HCV by specialists or nonspecialists
• Risk of HCC after SVR in patients with HCV

Presenter:

Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine I 
JW Goethe University Hospital 
Frankfurt, Germany

Follow along with the downloadable slideset at: 
https://bit.ly/3FxIOwZ

Link to full program: 
https://bit.ly/3Y1tD6f

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.